| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Basic, applied research, and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Comparing Organizational Structures in Health Services |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
2,394 |
| Comparing approval procedures for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
24 |
| Comparing organizational structures in health services |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
| Demand versus Supply Side Cost-Sharing: Patients’ preferences |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
20 |
| Demand versus Supply Side Cost-Sharing: The users' perspective |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
22 |
| Demand versus Supply Side Cost-Sharing: The users' perspective |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
19 |
| Des « Nobels » de sciences économiques au service des systèmes de santé |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Des « Nobels » de sciences économiques au service des systèmes de santé |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
15 |
| Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan? |
0 |
0 |
0 |
7 |
0 |
0 |
2 |
92 |
| Drug approval decision times, international reference pricing and access to new drugs |
0 |
0 |
0 |
0 |
2 |
2 |
5 |
25 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
34 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
35 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
11 |
0 |
0 |
1 |
57 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
34 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
1 |
2 |
6 |
40 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
36 |
| Drug approval decision times, international reference pricing and strategic launches of new drugs |
0 |
0 |
1 |
10 |
0 |
7 |
11 |
68 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
67 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
52 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
46 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
17 |
1 |
1 |
1 |
90 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
| Drug launch timing and international reference pricing |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
23 |
| Enjeux tarifaires de la médecine génomique |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
| External Reference Pricing and Sequential Launching of Drugs |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
35 |
| External referencing and pharmaceutical price negotiation |
0 |
0 |
0 |
10 |
1 |
1 |
1 |
40 |
| External referencing and pharmaceutical price negotiation |
0 |
0 |
0 |
152 |
3 |
3 |
3 |
462 |
| External referencing and pharmaceutical price negotiation |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
29 |
| GPs’ Payment Contracts and their Referral Policy |
0 |
0 |
0 |
14 |
0 |
1 |
3 |
104 |
| GPs’ payment contracts and their referral practice |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
3 |
| Generic entry, price competition, and market segmentation in the prescription drug market-A comment |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
3 |
| Health Services: Incentives and Access. Keynote speech |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
21 |
| Health services: Incentives and access |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
19 |
| Healthcare providers’ payments with personalized medicine |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
11 |
| Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality |
0 |
0 |
1 |
1 |
1 |
1 |
2 |
5 |
| How Should Donors Give Foreign Aid? Project Aidversus Budget Support |
0 |
0 |
0 |
63 |
0 |
0 |
0 |
375 |
| How should donors give foreign aid ? A theoretical comparison of aid modalities |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
19 |
| How should donors give foreign aid? Project aid versus budget support |
0 |
0 |
0 |
171 |
2 |
2 |
8 |
652 |
| How should donors give foreign aid? Project aid versus budget support |
0 |
0 |
0 |
111 |
1 |
2 |
2 |
279 |
| Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
17 |
1 |
2 |
3 |
43 |
| Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
28 |
| Incentives to patients versus incentives to health care providers: The users' perspective |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
34 |
| Incentives to patients versus incentives to health care providers: The users’ perspective |
0 |
0 |
0 |
27 |
0 |
1 |
1 |
62 |
| La Médecine personnalisée |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
32 |
| Médecine personnalisée et prix des médicaments |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
23 |
| On the relationship between the negociated price of pharmaceuticals and the patients' co-payment |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
36 |
| On the relationship between the negociated price of pharmaceuticals and the patients' co-payment |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
65 |
| Payment mechanism and GP self-selection: capitation versus fee for service |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
54 |
| Perception du lien entre mode de rémunération et comportement des médecins |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
29 |
| Perception du lien entre mode de rémunération et comportement des médecins |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
| Personalized medicine and drug prices |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
44 |
| Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
44 |
| Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
2 |
2 |
2 |
31 |
| Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
46 |
| Physicians Balance Billing, Supplemental Insurance and Access to Health Care |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
41 |
| Physicians self selection of a payment mechanism: Capitation versus fee-for-service |
0 |
0 |
0 |
31 |
0 |
1 |
1 |
90 |
| Physicians self selection of a payment mechanism: Capitation versus fee-for-service |
0 |
0 |
0 |
30 |
1 |
2 |
6 |
294 |
| Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
14 |
| Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
13 |
| Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
| Physicians' balance billing, supplemental insurance and access to health care |
0 |
0 |
1 |
16 |
1 |
1 |
4 |
91 |
| Physicians’ balance billing, supplemental insurance and access to health care |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
55 |
| Physicians’ balance billing, supplemental insurance and access to health care |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
114 |
| Preferences for Demand versus Supply Side Cost-Sharing |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
14 |
| Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry |
0 |
0 |
1 |
3 |
0 |
0 |
3 |
9 |
| Pricing and Welfare of Parallel Imports in the Pharmaceutical Industry |
0 |
0 |
0 |
165 |
2 |
2 |
2 |
445 |
| Primary Care, Gatekeeping and Incentives |
0 |
0 |
0 |
0 |
2 |
3 |
6 |
97 |
| Regulation and Altruism |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
35 |
| Regulation and Altruism |
0 |
0 |
0 |
29 |
1 |
2 |
3 |
50 |
| Regulation and altruism |
0 |
0 |
0 |
9 |
1 |
2 |
4 |
39 |
| Regulation and altruism |
0 |
0 |
0 |
27 |
0 |
1 |
1 |
41 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
11 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
20 |
| Research funding and price negotiation for new drugs |
0 |
0 |
2 |
55 |
0 |
0 |
5 |
45 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
7 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
47 |
2 |
2 |
3 |
24 |
| Research funding and price negotiation for new drugs |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
20 |
| The pricing of physicians' services with distant medicine and health insurance |
0 |
0 |
0 |
8 |
0 |
1 |
1 |
29 |
| The pricing of physicians' services with distant medicine and health insurance |
0 |
1 |
3 |
8 |
0 |
1 |
4 |
11 |
| Treatment and referral decisions under different physician payment mechanisms |
0 |
0 |
0 |
39 |
0 |
0 |
2 |
106 |
| Total Working Papers |
0 |
1 |
9 |
1,165 |
41 |
72 |
156 |
7,704 |
LogEc is hosted by the
Örebro University School of Business.